Combination of dualtargeted therapies and chemotherapy shows high response rates in BRAFmutated metastatic colorectal cancer
Jan 25, 2025
Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy regimen, according to results from the PhaseIII BREAKWATER trial.
https://www.sciencedaily.com/releases/2025/01/250125152749.htm
Respond, make new discussions, see other discussions and customize your news...

To add this website to your home screen:

1. Tap tutorialsPoint

2. Select 'Add to Home screen' or 'Install app'.

3. Follow the on-scrren instructions.

Feedback
FAQ
Privacy Policy
Terms of Service